Fig 2: Resveratrol hampers IL-6R/STAT3 signaling in 3D ovarian cancer spheroids. (A) Experimental timeline of the 3D spheroids-forming assay. (B–D) Western blotting showing the expression of IL-6R (B), pSTAT3 (Tyr705)/STAT3 (C), and ARH-I (D) on day 10. The densitometric analysis of Western blotting representative of three replicates is included.

Fig 3: In vitro IL-6 bioassay with engineered human cells. (A) Signal transduction detection by luminescence of cells incubated with IL-6 (143 nM) treated with HOCl from 0 to 143 µM. At concentrations of IL-6 between 4.2 and 111 ng/mL, all concentrations of HOCl tested produced results that were significantly different from the control (p < 0.05). (B) Signal transduction detection by luminescence for cells incubated with untreated IL-6 (143 nM) and IL-6 (143 nM) treated with HOCl, HOBr, and NCT. The results at all concentrations of HOCl, HOBr, and NCT were significantly different from the controls (p < 0.05). (C) Inhibition of IL-6 (143 nM) binding to the IL-6R in the presence of various concentrations of the anti-IL-6R antibody. (D) Signal transduction detection for cells incubated with IL-6 (143 nM) pre-treated with HOCl, NCT, or HOBr and then subsequently treated with native IL-6.